# EDGAR Filing Document

**Accession Number:** 0000844856
**File Stem:** 0001493152-26-022965
**Filing Date:** 2026-5
**Character Count:** 78801
**Document Hash:** fd564a6dc2114f1c786ab36fa81bdd0f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-022965.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001493152-26-022965

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 56

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Healthier Choices Management Corp.
- **CENTRAL INDEX KEY:** 0000844856
- **STANDARD INDUSTRIAL CLASSIFICATION:** TOBACCO PRODUCTS [2100]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 841070932
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36469
- **FILM NUMBER:** 26977840

**BUSINESS ADDRESS:**
- **STREET 1:** 3800 NORTH 28TH WAY
- **CITY:** HOLLYWOOD
- **STATE:** FL
- **ZIP:** 33020
- **BUSINESS PHONE:** 305-600-5004

**MAIL ADDRESS:**
- **STREET 1:** 3800 NORTH 28TH WAY
- **CITY:** HOLLYWOOD
- **STATE:** FL
- **ZIP:** 33020

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VAPOR CORP.
- **DATE OF NAME CHANGE:** 20100108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MILLER DIVERSIFIED CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

**Or**

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _____ to _____**

**Commission file number: 001-36469**

**HEALTHIER CHOICES MANAGEMENT CORP.**

**(Exact name of Registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **84-1070932** |
| **(State or other jurisdiction of** | **(I.R.S. Employer** |
| **incorporation or organization)** | **Identification No.)** |

---

---

| | |
|:---|:---|
| **3800 North 28th Way**<br>**Hollywood, Florida** | **33020** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: 305-600-5004**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share HCMC | OTC Pink Marketplace |

---

As of May 14, 2026, there were 527,156,418,606 shares of the registrant's common stock, par value $0.0001 per share, outstanding.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **PAGE** |
| [PART I FINANCIAL INFORMATION](#wg_001) | 3 |
| [ITEM 1. Financial Statements](#wg_002) | 3 |
| [Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025](#wg_003) | 3 |
| [Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025 (Unaudited)](#wg_004) | 4 |
| [Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity for the Three Months Ended March 31, 2026 and 2025 (Unaudited)](#wg_005) | 5 |
| [Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025 (Unaudited)](#wg_006) | 6 |
| [Notes to Condensed Consolidated Financial Statements (Unaudited)](#wg_007) | 7 |
| [ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#wg_008) | 14 |
| [ITEM 3. Quantitative and Qualitative Disclosures about Market Risk](#wg_009) | 16 |
| [ITEM 4. Controls and Procedures](#wg_010) | 16 |
| [PART II OTHER INFORMATION](#wg_011) | 18 |
| [ITEM 1. Legal Proceedings](#wg_012) | 18 |
| [ITEM 1A. Risk Factors](#wg_013) | 18 |
| [ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds](#wg_014) | 18 |
| [ITEM 3. Defaults Upon Senior Securities](#wg_015) | 18 |
| [ITEM 4. Mine Safety Disclosures](#wg_016) | 18 |
| [ITEM 5. Other Information](#wg_017) | 18 |
| [ITEM 6. Exhibits](#wg_018) | 19 |
| [Signatures](#wg_019) | 20 |
| [Exhibit 31.1](ex31-1.htm) |  |
| [Exhibit 31.2](ex31-2.htm) |  |
| [Exhibit 32.1](ex32-1.htm) |  |
| [Exhibit 32.2](ex32-2.htm) |  |

---

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**HEALTHIER CHOICES MANAGEMENT CORP.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026**<br> **(Unaudited)** | December 31, 2025 |
| **ASSETS** |  |  |
| **CURRENT ASSETS** |  |  |
| Cash and cash equivalent | $**1137634** | $1140488 |
| Accounts receivable, net | **199** | 199 |
| Inventories | **36756** | 36148 |
| Prepaid expenses and vendor deposits | **44475** | 62891 |
| Restricted cash | **100000** | 100000 |
| **TOTAL CURRENT ASSETS** | **1319064** | 1339726 |
| Property, plant, and equipment, net of accumulated depreciation | **5691** | 7789 |
| Intangible assets, net of accumulated amortization | **109245** | 119026 |
| Right of use asset – operating lease, net | **534** | 1329 |
| Other assets |  | - |
| **TOTAL ASSETS** | $**1434534** | $1467870 |
| **LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT** |  |  |
| **CURRENT LIABILITIES** |  |  |
| Accounts payable and accrued expenses | $**660199** | $1588935 |
| Loan payable, current | **1367735** |  |
| Operating lease liability, current | **534** | 1329 |
| Due to related party | **115255** | - |
| **TOTAL LIABILITIES** | **2143723** | 1590264 |
| **COMMITMENTS AND CONTINGENCIES (SEE NOTE 9)** |  |  |
| **CONVERTIBLE PREFERRED STOCK** |  |  |
| Series E redeemable convertible preferred stock, $1,000 par value per share, 14,722 shares authorized, 1,111 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively; aggregate liquidation preference of $1.1 million as of March 31, 2026 and December 31, 2025, respectively. | **1111100** | 1111100 |
| **STOCKHOLDERS' DEFICIT** |  |  |
| Common Stock, $0.0001 par value per share, 750,000,000,000 shares authorized; 527,156,418,606 and 525,156,418,606 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | **52715642** | 52515642 |
| Additional paid-in capital | **28304404** | 28304404 |
| Accumulated deficit | **(82840335)** | (82053540) |
| **TOTAL STOCKHOLDERS' DEFICIT** | **(1820289)** | (1233494) |
| **TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT** | $**1434534** | $1467870 |

---

*See notes to unaudited condensed consolidated financial statements*

**HEALTHIER CHOICES MANAGEMENT CORP.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | 2025 |
| **SALES, NET** | $**-** | $1780 |
| **COST OF SALES** | **-** | 1478 |
| **GROSS PROFIT** | **-** | 302 |
| **OPERATING EXPENSES** | **806624** | 2169715 |
| **LOSS FROM OPERATIONS** | **(806624)** | (2169413) |
| **OTHER INCOME (EXPENSE)** |  |  |
| Other income, net | **12500** | (22809) |
| Interest income, net | **7329** | 8546 |
| **TOTAL OTHER INCOME (EXPENSE), NET** | **19829** | (14263) |
| **NET LOSS** | $**(786795)** | $(2183676) |
| **NET LOSS PER SHARE-BASIC AND DILUTED** | $**-** | $- |
| **WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING-BASIC AND DILUTED** | **526423085273** | 481266632384 |

---

*See notes to unaudited condensed consolidated financial statements*

**HEALTHIER CHOICES MANAGEMENT CORP.**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)**

**FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**

**(UNAUDITED)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series E Convertible**<br> **Preferred Stock** | **Series E Convertible**<br> **Preferred Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br> **Paid-In**<br>**Capital** | **Accumulated**<br>**Deficit** |<br>**Total** |
| **Balance – January 1, 2026** | **1111** | $**1111100** | **525156418606** | $**52515642** | $**28304404** | $**(82053540)** | $**(1233494)** |
| Issuance of common stock for debt settlement |  |  | 2000000000 | 200000 |  |  | 200000 |
| Net loss | - | - | - | - | - | (786795) | (786795) |
| **Balance – March 31, 2026** | **1111** | $**1111100** | **527156418606** | $**52715642** | $**28304404** | $**(82840335)** | $**(1820289)** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series E Convertible Preferred Stock** | **Series E Convertible Preferred Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br> **Paid-In**<br>**Capital** | **Accumulated**<br>**Deficit** |<br>**Total** |
| **Balance – January 1, 2025** | **1111** | $**1111100** | **481266632384** | $**48126663** | $**25347774** | $**(75035595)** | $**(1561158)** |
| Stock-based compensation expense |  |  |  |  | 1122584 |  | 1122584 |
| Net loss | - | - | - | - | - | (2183676) | (2183676) |
| **Balance – March 31, 2025** | **1111** | $**1111100** | **481266632384** | $**48126663** | $**26470358** | **(77219271)** | $**(2622250)** |

---

*See notes to unaudited condensed consolidated financial statements*

**HEALTHIER CHOICES MANAGEMENT CORP.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | 2025 |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| Net loss from continuing operations | $**(786795)** | $(2183676) |
| *Adjustments to reconcile net loss to net cash used in operating activities:* |  |  |
| Depreciation and amortization | **11879** | 13230 |
| Amortization of debt discount | **106** |  |
| Loss on asset disposal | **-** | 22809 |
| Amortization of right-of-use asset | **795** | 766 |
| Stock-based compensation expense | **-** | 1122583 |
| *Changes in operating assets and liabilities:* |  |  |
| Inventories | **(608)** | 1369 |
| Prepaid expenses and vendor deposits | **18416** | 41500 |
| Other current assets | **-** | (3085) |
| Due to related party | **1862** | 2399 |
| Accounts payable and accrued expenses | **146264** | (1740) |
| Lease liability | **(795)** | (766) |
| **NET CASH USED IN OPERATING ACTIVITIES** | **(608876)** | (984611) |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| Purchases of property and equipment | **-** | - |
| **NET CASH USED IN INVESTING ACTIVITIES** | **-** | - |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| Proceeds from loan agreement | **492629** |  |
| Payment on line of credit | **-** | (453232) |
| Due to related party | **113393** | 966584 |
| **NET CASH PROVIDED BY FINANCING ACTIVITIES** | **606022** | 513352 |
| **NET DECREASE IN CASH, CASH EQUIVALENT AND RESTRICTED CASH** | **(2854)** | (471259) |
| **CASH, CASH EQUIVALENT AND RESTRICTED CASH— BEGINNING OF PERIOD** | **1240488** | 1746799 |
| **CASH, CASH EQUIVALENT AND RESTRICTED CASH — END OF PERIOD** | $**1237634** | $1275540 |
| **SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION** |  |  |
| Cash paid for interest | $**-** | $582 |
| Cash paid for income tax | $**-** | $- |
| **NON-CASH INVESTING AND FINANCING ACTIVITIES** |  |  |
| Issuance of promissory note in connection with debt settlement | $**875000** | $- |
| Issuance of common stock to settle debt | $**200000** | $- |

---

*See notes to unaudited condensed consolidated financial statements.*

**HEALTHIER CHOICES MANAGEMENT CORP.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(UNAUDITED)**

**NOTE 1. ORGANIZATION**

***Organization***

Healthier Choices Management Corp. (the "Company" or "HCMC") is a holding company focused on monetizing its intellectual property through its wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC. The Company seeks to further monetize its patent suite through development and production of its patented products, including the Q-Cup™ technology and Imitine, licensing and royalty agreements, and enforcement actions against infringers of its intellectual property.

The Company administers and intends to augment its intellectual property portfolio via its wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC.

The Company continues to promote its patented Q-Cup™ technology directly to consumers in the vaping market. This cutting-edge design includes a small quartz cup that users can fill with cannabis or CBD concentrate. Once placed in a Q-Cup™ Tank or Globe, the cup is heated externally without direct contact with the concentrate. This innovative approach provides greater efficiency and a convenient solution for consumers who vape concentrates for both medicinal and recreational use.

In connection with the Company's strategic initiative to monetize its intellectual property through the development and production of new products, the Company entered into a Distribution Agreement (the "Distribution Agreement") with a third party distributor on November 27, 2025, to commercialize a new product line utilizing the Company's NatureTine™ ingredient (the "Quitcubes" product line). Under the Distribution Agreement, the distributor is responsible for marketing, customer fulfillment, and website management, while the Company is responsible for manufacturing the product.

The launch of the Quitcubes product line, originally anticipated to commence in the first quarter of 2026, was delayed as the Company worked to establish the necessary operational infrastructure to execute the Distribution Agreement. As a result, the Company recorded no net sales from the Quitcubes product line for the three months ended March 31, 2026.

Subsequent to March 31, 2026, the Company has made significant progress in establishing the required operational infrastructure. Management is now working with the distributor to finalize the remaining steps and expects the official commercial launch of the Quitcubes product line to occur in June 2026. However, there can be no assurance that the launch will occur as planned, or if launched, that the product line will generate material revenue or positive cash flow.

***Segment Reporting***

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the operating decision makers, or decision-making group, in making decisions on how to allocate resources and assess performance. The Company operates as a single reportable segment, as the chief operating decision maker ("CODM", the Company's Chief Executive Officer, Jeffrey Holman) reviews financial performance and makes decisions on a consolidated basis.

**NOTE 2. GOING CONCERN AND MANAGEMENT'S PLANS**

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.

The Company currently and historically has reported net losses and cash outflows from operations. As of March 31, 2026, the Company had cash and cash equivalent of approximately $1.1 million and negative working capital of $0.8 million. The Company's liquidity needs through March 31, 2026 have been satisfied through financing agreement with private lenders.

On March 27, 2026, the Company entered into a $5 million loan agreement with Sabby Volatility Warrant Master Fund, Ltd. (the "Sabby Loan Agreement"). Concurrently, the Company terminated its prior $5 million credit facility with a private lender. In connection with the Sabby Loan Agreement, the Company received an initial advance of $500,000. The remaining $4.5 million is available to the Company subject to the terms and conditions of the Sabby Loan Agreement.

Management has made plans to reduce certain costs and raise needed capital, however there can be no assurance the Company can successfully implement these plans. The success of these plans is dependent upon various factors, foremost being the ability to reduce outside consulting expenses and the ability to secure additional capital from outside investors. There can be no assurance that such plans will be successful.

Management believes that the Company's cash on hand, together with the availability of up to $4.5 million in additional draws under the Sabby Loan Agreement, will enable the Company to meet its obligations and capital requirements for at least the twelve months from the date of this filing. Accordingly, no adjustment has been made to the financial statements to account for this uncertainty.

**NOTE 3. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES**

***Basis of Consolidation***

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Regulation S-X and do not include all the information and disclosures required by GAAP. The Company has made estimates and judgments affecting the amounts reported in the Company's unaudited condensed consolidated financial statements and the accompanying notes. The actual results experienced by the Company may differ materially from the Company's estimates. The condensed consolidated financial information is unaudited but reflects all normal adjustments that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods presented.

These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on March 27, 2026. The condensed consolidated balance sheet as of March 31, 2026 was derived from the Company's audited 2025 financial statements contained in the above referenced Form 10-K. Results of the three months ended March 31, 2026, are not necessarily indicative of the results to be expected for the full year ending December 31, 2026.

***Significant Accounting Policies***

There have been no material changes in the Company's significant accounting policies to those previously disclosed in the 2025 Annual Report.

**NOTE 4. CONCENTRATIONS**

***Cash, Cash Equivalent and Restricted Cash***

The Company considers all highly liquid instruments with an original maturity of three months or less, when purchased, to be cash and cash equivalent. The majority of the Company's cash and cash equivalent are concentrated in one large financial institution, which is in excess of Federal Deposit Insurance Corporation (FDIC) coverage.

A summary of the financial institution that had cash, cash equivalent and restricted cash in excess of FDIC limits of $250,000 on March 31, 2026 and December 31, 2025 is presented below:

SCHEDULE OF CASH AND CASH EQUIVALENT AND RESTRICTED CASH IN EXCESS OF FDIC LIMIT

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | December 31, 2025 |
| Total cash and cash equivalent in excess of FDIC limits of $250,000 | $**887394** | $880191 |

---

The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests, as deposits are held in excess of federally insured limits. The Company has not experienced any losses in such accounts.

The following table provides a reconciliation of cash, cash equivalent and restricted cash to amounts shown in unaudited condensed consolidated statements of cash flow:

SCHEDULE OF RECONCILIATION OF CASH, CASH EQUIVALENT AND RESTRICTED CASH

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | December 31, 2025 |
| Cash and cash equivalent | $**1137634** | $1140488 |
| Restricted cash | **100000** | 100000 |
| Total cash and restricted cash | $**1237634** | $1240488 |

---

***Restricted Cash***

The Company's restricted cash consisted of cash balances which were restricted as to withdrawal or usage under the August 18, 2022 Securities Purchase Agreement for the purpose of funding any amounts due under the Series E Certificate of Designation upon the redemption of the Series E Preferred Stock.

**NOTE 5. PROPERTY AND EQUIPMENT**

Property and equipment consist of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | December 31, 2025 |
| Furniture and fixtures | **33895** | **33895** |
| Computer hardware & equipment | **50522** | **50522** |
| Other fixed assets | **8056** | **8056** |
| Property and equipment, gross | **92473** | **92473** |
| Less: accumulated depreciation and amortization | **(86782)** | **(84684)** |
| Total property, plant, and equipment | $**5691** | $**7789** |

---

The Company incurred approximately $2,000 of depreciation expense for the three months ended March 31, 2026 and 2025, respectively.

**NOTE 6. INTANGIBLE ASSETS**

The Company's intangible assets consist of patents and capitalized legal fees related to the patents. Intangible assets, net are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **March 31, 2026** | **Useful Lives**<br> **(Years)** | **Gross Carrying**<br> **Amount** | **Accumulated**<br> **Amortization** | **Net**<br> **Carrying**<br> **Amount** |
| Patent | **10 years** | $**397165** | $**(287920)** | $**109245** |
| Intangible assets, net |  | $**397165** | $**(287920)** | $**109245** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| December 31, 2025 | Useful Lives <br> (Years) | Gross Carrying <br> Amount | Accumulated <br> Amortization | Net <br> Carrying <br> Amount |
| Patent | 10 years | 397165 | (278139) | 119026 |
| Intangible assets, net |  | $397165 | $(278139) | $119026 |

---

Intangible assets are amortized on a straight-line basis over their estimated useful lives. Amortization expense was approximately $10,000 and $11,000 for the three months ended March 31, 2026 and 2025, respectively. Future annual estimated amortization expense is as follows:

---

| | |
|:---|:---|
| **Years ending December 31,** | |
| 2026 (remaining nine months) | $28399 |
| 2027 | 32564 |
| 2028 | 23333 |
| 2029 | 12475 |
| 2030 | 3428 |
| Thereafter | 9046 |
| **Total** | $**109245** |

---

**NOTE 7. DEBT**

***Private Lender Credit Facilities***

On November 7, 2024, the Company entered into a $5,000,000 revolving line of credit agreement with a private lender (the "Prior Facility"). The Prior Facility bore interest at 12% per annum, payable quarterly, and was scheduled to mature on April 30, 2026. On April 11, 2025, the Company and the lender amended the agreement to extend the maturity date to December 31, 2026. On March 27, 2026, the Company terminated the Prior Facility. No amounts were outstanding under the Prior Facility at the time of termination.

***Sabby Volatility Warrant Master Fund, Ltd. Credit Facility***

On March 27, 2026, the Company entered into a Loan Agreement (the "Sabby Loan Agreement") with Sabby Volatility Warrant Master Fund, Ltd. (the "Lender"), providing for a $5,000,000 unsecured revolving line of credit. The Sabby Facility matures on December 31, 2026, unless extended at the Lender's sole discretion. Borrowings under the Sabby Facility bear interest at 12% per annum. Interest is payable on the Maturity Date, together with the outstanding principal balance. The Company may request advances from time to time, subject to the terms and conditions of the Sabby Loan Agreement. In connection with the initial funding under the Sabby Facility, the Company received an advance of $500,000 (the "Initial Advance").

As of March 31, 2026, the outstanding principal balance under the Sabby Facility was $500,000. The remaining $4,500,000 is available for future advances, subject to the terms and conditions of the Sabby Loan Agreement. Interest expense for the three months ended March 31, 2026 was approximately $1,000, compared to approximately $0 for the same period in 2025. Interest expense is recognized as incurred based on the outstanding principal balance and the contractual interest rate.

***Promissory Note***

 ****

On February 1, 2026, the Company entered into a Stock Purchase and Satisfaction of Debt Agreement with a legal firm to settle outstanding legal fees in excess of $1.4 million. In connection with this agreement, the Company issued $875,000 promissory note to this legal firm. The Note is non-interest-bearing and has no fixed maturity date. The principal amount of $875,000 becomes due immediately upon the first occurrence of any of the following events:

● Equity financing of $4 million or more

● Change of control of the Company

● The Chief Executive Officer no longer serves in that role

● Bankruptcy or dissolution of the Company

● The Company has $2 million or more in cash

The note is classified as a current liability and recorded at face value. The issuance of the Note was a non-cash financing activity. Accordingly, it has been excluded from the statement of cash flows and disclosed in the supplemental schedule of non-cash investing and financing activities.

**NOTE 8. STOCKHOLDERS' EQUITY**

***Series E Convertible Preferred Stock***

On August 18, 2022, the Company entered into a Securities Purchase Agreement ("Series E Preferred Stock") pursuant to which the Company sold and issued 14,722 shares of its Series E Redeemable Convertible Preferred Stock to institutional investors for $1,000 per share or an aggregate subscription of $13.25 million. The number of shares issued to each participant is based on subscription amount multiplied by conversion rate of 1.1111. The Company also incurred offering costs of approximately $410,000, which covers legal and consulting fee.

The HCMC Series E Preferred Stock shall have voting rights on as converted basis at the Company's next stockholders' meeting. However, as long as any shares of HCMC Series E Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the HCMC Series E Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the HCMC Series E Preferred Stock or alter or amend the Certificate of Designation, (b) increase the number of authorized shares of HCMC Series E Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing. Each share of Series E Preferred Stock shall be convertible, at any time and from time to time at the option of the Holder thereof, into that number of shares of Common Stock (subject to the beneficial ownership limitations). The initial conversion price for the HCMC Series E Preferred Stock shall equal $0.0001.

Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary that is not a Fundamental Transaction (as defined in the Certificate of Designation), the holders of HCMC Series E Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount equal to $1,000 per share of Series E Preferred Stock.

Unless earlier converted or extended as set forth below, a holder may require the redemption of all or a portion of the stated value of the HCMC Series E Preferred Stock either (1) six months after closing or (2) the time at which the balance is due and payable upon an event of default.

On March 1, 2023, the Company entered into a First Amendment to HCMC Series E Preferred Stock with each purchaser ("Purchaser") identified as those who participated in the HCMC Series E Preferred Stock, dated as of August 18, 2022. The parties amended the HCMC Preferred Stock related to the conversion payment whereby upon conversion of the Series E Preferred Stock prior to the record date for the Spin-Off, the Company will pay the Purchaser ten percent (10%) of the stated value of the Series E Preferred Stock converted. The record date is May 1, 2023.

On May 15, 2023, the Company and the Purchaser entered into the Second Amendment to the Securities Purchase Agreement, pursuant to which the Company agreed to extend the time period for the Conversion Payment eligibility to December 1, 2023. The Company filed an amendment to the Certificate of Designation to make the redemption price of the Preferred Stock (the "Redemption Price") equal the Stated Value regardless of the date on which it is redeemed. Prior to this amendment, the Redemption Price was discounted by 1% for each month after the seven-month anniversary of the Issue Date that the Purchaser elected not to redeem.

On October 30, 2023, the Company entered into a Third Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers. The parties agreed to: (1) set the initial conversion price for the Series E Preferred Stock to be the 5-day volume weighted average price measured using the 5 trading days preceding the purchase of the Series E Preferred Stock, (2) on the 40th calendar day (the "Reset Date") after the sale of the Series E Preferred Stock, reset the conversion price in the event the closing price of the Class A common stock on such date is less than the initial conversion, (3) have the reset conversion price equal a 10% discount to the 5-day volume weighted average price measured using the 5 trading days preceding the Reset Date; provided, however, in no instance will the conversion price be reset below 30% of the initial conversion price, and (4) amend the Completion Date to March 1, 2024.

On February 20, 2024, the Company entered into a Fourth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to June 1, 2024.

On April 8, 2024, the Company entered into a Fifth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to August 1, 2024.

On July 26, 2024, the Company entered into a Sixth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to November 1, 2024.

On November 27, 2024, the Company entered into a Seventh Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to May 31, 2025.

On April 11, 2025, the Company entered into an Eighth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to October 31, 2025.

On October 30, 2025, the Company entered into a Ninth Amendment to the Securities Purchase Agreement with its Series E Redeemable Convertible Preferred Stock purchasers, pursuant to which the Company and such parties agreed to amend the Completion Date to April 1, 2027.

Through March 31, 2026, 1,585 shares of Series E preferred stock have been cumulatively converted into 15,850,000,000 shares of common stock as a result of the Series E preferred stock conversion, and 12,026 shares of Series E preferred stock have been cumulatively redeemed, and approximately $12,004,000 has been paid for redemption. As of March 31, 2026, 1,111 shares of Series E preferred stock remained outstanding.

***Stock Options and Restricted Stock***

During the three months ended March 31, 2026 and 2025, no stock options of the Company were exercised into common stock.

All stock-based awards were fully amortized as of December 31, 2025. Accordingly, the Company recognized no stock-based compensation during the three months ended March 31, 2026, compared to $1,123,000 for the same period in 2025. Stock based compensation is included as part of total operating expenses in the accompanying unaudited condensed consolidated statements of operations.

***Debt Settlement through Issuance of Common Stock***

On December 31, 2025, the Company entered into a Stock Purchase and Satisfaction of Debt Agreement with Healthy Choice Wellness Corp. ("HCWC"), a related party. Pursuant to this agreement, the Company issued 43,889,786,222 shares of its common stock to HCWC at a contractual price of $0.00009 per share, in full and final settlement of a related party payable, which had a carrying value of $3,950,080 as of the settlement date. In accordance with the Company's accounting policy for related party transactions, the payable was extinguished at its carrying amount, and no gain or loss was recognized.

On February 1, 2026, the Company entered into a settlement agreement with a vendor to resolve approximately $1.3 million in outstanding accounts payable for past services. Under the terms of the agreement, the total obligation was reduced to $875,000, and the Company issued a non-interest bearing promissory note in that amount to the vendor. The remaining balance of the original obligation was satisfied through a combination of (i) the issuance of 2,000,000,000 shares of the Company's common stock valued at $0.0001 per share, totaling $200,000, and (ii) the recharacterization of a portion of the obligation as part of a contingent fee arrangement related to ongoing patent litigation.

***Earnings Per Share***

Basic earnings per share is computed using the weighted average number of common shares outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of common shares outstanding adjusted to include the potentially dilutive effect of stock awards. For the three months ended March 31, 2026 and 2025, diluted EPS is the same as basic EPS because all potentially dilutive securities are anti-dilutive due to the net loss. Under GAAP, diluted EPS must be disclosed even when equal to basic EPS. All potentially dilutive securities were excluded from the diluted EPS calculation because their inclusion would have been anti-dilutive (i.e., reduce the loss per share), which is not permitted under GAAP.

The following table summarizes the Company's securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

---

| | | |
|:---|:---|:---|
|  | As of March 31, | As of March 31, |
|  | **2026** | 2025 |
| Preferred stock | **11111000000** | 11111000000 |
| Stock options | **67587222200** | 67587222200 |
| Restricted stock | **-** | 26543750000 |
| Total | **78698222200** | 105241972200 |

---

The following table sets forth the computation of basic and diluted earnings per share attributable to the Company's stockholders.

SCHEDULE OF COMPUTATION OF BASIC AND DILUTED EARNINGS PER SHARE

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| NET LOSS | $(786795) | $(2183676) |
| BASIC AND DILUTED WEIGHTED AVERAGE COMMON SHARES | 526423085273 | 481266632384 |
| BASIC AND DILUTED NET LOSS PER SHARE | $- | $- |

---

**NOTE 9. COMMITMENTS AND CONTINGENCIES**

***Legal Proceedings***

There were two lawsuits in connection with alleged claimed battery defects for an electronic cigarette device. One has been dismissed by the court wherein the plaintiff settled with the Company's insurance carrier with no economic impact to the Company. In the second lawsuit, as of December 31, 2023, the Company had reached an arrangement with the plaintiff to resolve the matter, limiting potential exposure to $1.5 million which was reflected in accounts payable and accrued expenses, representing management's estimate of the probable settlement amount based on the current status of discussions. This arrangement was formalized by a signed agreement on July 1, 2024 and the Company has accrued $1.5 million at June 30, 2024. As of May 31, 2025, the Company already paid $1.5 million in full.

On September 26, 2023, HCMC filed a patent infringement lawsuit against R.J. Reynolds Vapor Company ("RJR") in the U.S. District Court for the Middle District of North Carolina in connection with HCMC's assertions that RJR's Vuse electronic cigarette infringes one of HCMC's patents.

On November 17, 2023, RJR filed a motion to dismiss the action. HCMC opposed on December 22, 2023.

On September 18, 2024, RJR filed an inter partes review of the patent-in-suit at the United States Patent and Trademark Office ("USPTO").

In March 2026, the Patent Trial and Appeal Board issued a decision in favor of RJR in the ongoing patent dispute. The Company is currently evaluating its options and expects to file an appeal of the ruling.

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations as of March 31, 2026. With respect to legal costs, we record such costs as incurred.

**NOTE 10. RELATED PARTY TRANSACTIONS**

Prior to the Spin-Off, HCWC was a subsidiary of HCMC. Following the Spin-Off on September 13, 2024, the Company and HCWC operate as separate, publicly traded companies, though they remain related parties due to common ownership history and ongoing agreements.

***Due to Related Party***

Prior to the Spin-Off, there was no intercompany agreement between the Company and HCWC. Management has determined that intercompany receivables and payables will be settled within twelve months after the balance sheet date. As a result, the Company's intercompany balances are reflected as "due to" or "due from" accounts in the consolidated balance sheets. After the Spin-Off, the Company and HCWC provided services to each other pursuant to the separation agreements to facilitate a smooth transition. The Company had a net due to related party balance of $0.1 million and $0 million to HCWC as of March 31, 2026 and December 31, 2025, respectively.

***Settlement of Related Party Payable***

On December 31, 2025, the Company entered into a Stock Purchase and Satisfaction of Debt Agreement with HCWC to settle the outstanding related party payable. Pursuant to this agreement, the Company issued 43,889,786,222 shares of its common stock to HCWC in full and final settlement of the payable, which had a carrying value of $3,950,080 as of the settlement date. The shares were issued at a contractual price of $0.00009 per share.

In accordance with ASC 850, Related Party Disclosures, and SAB Topic 5.T, transactions involving related parties are recorded based on their substance rather than merely their legal form. Related party transactions cannot be presumed to be carried out on an arm's-length basis. Accordingly, the payable was extinguished at its carrying amount of $3,950,080, and no gain or loss was recognized. The substance of this transaction is a capital transaction, a conversion of intercompany funding to equity, not a gain-generating event.

For disclosure purposes only, the Company determined the fair value of the common stock issued as of December 31, 2025 in accordance with ASC 820, Fair Value Measurement. HCWC, as the investor, performed an impairment assessment of its investment in the Company using a third-party valuation. That assessment, which utilized a multi-method approach including observable and unobservable inputs, concluded that the fair value of the Company's common stock exceeded HCWC's carrying value; therefore, no impairment was recorded.

***Agreements with HCWC***

The Company entered into several agreements with HCWC that, among other things, affect the separation and govern the relationship of the parties following the Spin-Off. These agreements include:

● a Separation Agreement that sets forth HCMC's and HCWC's agreements regarding the principal actions that both parties take in connection with the Spin-Off and aspects of our relationship following the Spin-Off;

● a Transition Services Agreement pursuant to which HCMC and HCWC provide each other specified services on a transitional basis to help ensure an orderly transition following the Spin-Off.

● a Tax Matters Agreement ("TMA") that governs the respective rights, responsibilities and obligations of HCMC and HCWC after the Spin-Off with respect to all tax matters and includes restrictions to preserve the tax-free status of the Spin-Off; and

● an Employee Matters Agreement ("EMA") that addresses employment, compensation and benefits matters, including the allocation and treatment of assets and liabilities arising out of employee compensation and benefits programs in which our employees participated prior to the Spin-Off.

Under the terms of the transition services agreement, the HCMC and HCWC provide to each other, on a transitional basis, certain services or functions, including information technology, accounting, human resources, and payroll functions. Generally, these services continue for a period of up to one year following the Spin-Off. Consideration and costs for the transition services are determined using several billing methodologies as described in the agreements, including customary billing and pass-through billing.

**NOTE 11. SUBSEQUENT EVENTS**

In accordance with FASB ASC 855-10, the Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed consolidated financial statements were available to be issued. Based upon this review, the Company identified the following subsequent event that would have required disclosure in the condensed consolidated financial statements.

Subsequent to March 31, 2026, the Company entered into a three-year consulting agreement with a third-party consultant effective April 24, 2026. Under the agreement, the consultant will receive warrants to purchase 10 billion shares of common stock annually at $0.0001 per share, for three years. The consultant will provide crypto acquisition strategy services, including identifying, purchasing, and advising on the sale of crypto tokens. The Company may terminate the agreement for cause, upon which only vested warrants are payable.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF CONDENSED CONSOLIDATED OPERATIONS**

The following discussion and analysis should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements. The terms "we," "us," "our," and the "Company" refer to Healthier Choices Management Corp. and its wholly-owned subsidiaries, HCMC Intellectual Property Holdings, LLC and The Vape Store, Inc. ("Vape Store"). All intercompany accounts and transactions have been eliminated in consolidation.

**Company Overview**

Healthier Choices Management Corp. is a holding company focused on monetizing its intellectual property through its wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC. The Company seeks to further monetize its patent suite through development and production of its patented products, including the Q-Cup™ technology and Imitine, licensing and royalty agreements, and enforcement actions against infringers of its intellectual property.

Through its wholly owned subsidiary HCMC Intellectual Property Holdings, LLC, the Company manages and intends to expand on its intellectual property portfolio.

Additionally, the Company markets its patented the Q-Cup™ technology under the vape segment; this patented technology is based on a small, quartz cup called the Q-Cup™, which a customer partially fills with either cannabis or CBD concentrate (approximately 50mg) purchased from a third party. The Q-Cup™ is then inserted into the Q-Cup™ Tank or Globe, that heats the cup from the outside without coming in direct contact with the solid concentrate. This Q-Cup™ technology provides significantly more efficiency and an "on the go" solution for consumers who prefer to vape concentrates either medicinally or recreationally.

As disclosed in Note 1 to the condensed consolidated financial statements, the Company entered into a Distribution Agreement on November 27, 2025, to commercialize a new product line, Quitcubes, utilizing the Company's NatureTine™ ingredient. The distributor is responsible for marketing, customer fulfillment, and website management, while the Company is responsible for manufacturing. The launch was originally anticipated in the first quarter of 2026 but was delayed as the Company established the necessary operational infrastructure. As a result, the Company recorded no net sales from Quitcubes for the three months ended March 31, 2026. Subsequent to quarter end, the Company has made significant progress and expects the official commercial launch to occur in June 2026. Management believes the successful launch of Quitcubes is critical to generating future revenue and addressing the Company's recurring losses.

***Liquidity***

The unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of any uncertainties related to our going concern assessment. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The Company currently and historically has reported net losses and cash outflows from operations. As of March 31, 2026, the Company had cash and cash equivalent of approximately $1.1 million and negative working capital of $0.8 million. The Company's liquidity needs through March 31, 2026 have been satisfied through financing agreement with private lenders.

On March 27, 2026, the Company terminated its prior $5 million credit facility with a private lender, and entered into a new $5 million Sabby Loan Agreement. The Sabby Facility matures on December 31, 2026, bears interest at 12% per annum, and allows for advances from time to time subject to the terms and conditions of the loan agreement. In connection with the Sabby Facility, the Company received an initial advance of $500,000. The remaining $4.5 million is available for future draws.

Management has made plans to reduce certain costs and raise the capital needed, however there can be no assurance the Company can successfully implement these plans. The success of these plans is dependent upon various factors, foremost being the ability to reduce outside consulting expenses and the ability to secure additional capital from outside investors. There can be no assurance that such plans will be successful.

Management believes that the Company's cash on hand, together with the availability of up to $4.5 million in additional draws under the Sabby Loan Agreement, will enable the Company to meet its obligations and capital requirements for at least twelve months from the date these financial statements are issued. Accordingly, no adjustment has been made to the financial statements to account for this uncertainty.

**Factors Affecting Our Performance**

We believe the following factors affect our performance:

***Pending Patent***: We have developed, trademarked and are preparing to commercialize additional products. We include product development expenses as part of our operating expenses. In October 2018, we announced the granting of three US patents related to our Q-Cup™ technology. In addition, we have a suite of patent applications pending in the United States. There is no assurance that we will be awarded patents for any of these pending patent applications. There is no assurance that we can monetize the patents.

***Manufacturing***: We have no manufacturing capabilities and do not intend to develop any manufacturing capabilities. Third party manufacturers make our products to meet our design specifications. We depend on third party manufacturers for our vaporizer e-liquid and accessories. Any interruption in supply and or consistency of our products may harm our relationships and reputation with customers, and have a material adverse effect on our business, results of operations and financial condition. In order to minimize the risk of supply interruption, we currently utilize several third-party manufacturers to manufacture our products to our specifications.

**Results of Operations**

The following table sets forth our unaudited condensed consolidated Statements of Operations for the three months ended March 31, 2026 and 2025 that is used in the following discussions of our results of operations:

---

| | | | |
|:---|:---|:---|:---|
|  | Three Months Ended March 31, | Three Months Ended March 31, | |
|  | **2026** | 2025 | 2026 to 2025<br>Change $ |
| **SALES, NET** | $**-** | $1780 | $(1780) |
| **COST OF SALES** | **-** | 1478 | (1478) |
| **GROSS PROFIT** | **-** | 302 | (302) |
| **OPERATING EXPENSES** | **806624** | 2169715 | (1363091) |
| **LOSS FROM OPERATIONS** | **(806624)** | (2169413) | 1362789 |
| **OTHER INCOME (EXPENSE)** |  |  |  |
| Interest income, net | **7329** | 8546 | (1217) |
| Other income, net | **12500** | (22809) | 35309 |
| **TOTAL OTHER INCOME (EXPENSE), NET** | **19829** | (14263) | 34092 |
| **NET LOSS** | $**(786795)** | $(2183676) | $1396881 |

---

Net sales and cost of sales were de minimis for the three months ended March 31, 2026 and 2025. The Company closed all its brick-and-mortar retail vape stores, as management had shifted its retail sales focus to the wholesale and online channel. The sales and cost of sales for the three months ended March 31, 2026 and 2025 continued to be significantly impacted by the inability to bring new products to market via distribution.

Total operating expenses decreased by $1.4 million to $0.8 million for the three months ended March 31, 2026, compared to $2.2 million for the same period in 2025. The decrease was primarily attributable to a $1.1 million reduction in stock-based compensation expense, as well as a $0.3 million decrease in professional fees, payroll and benefits, and insurance expense.

Total other income (expense), net $20,000 for the three months ended March 31, 2026 was mainly attributable to interest income of approximately $7,000 and $13,000 miscellaneous income. Total other income (expense), net of $14,000 for the three months ended March 31, 2025 consists of $23,000 loss on asset disposal offset by net interest income of $9,000.

***Liquidity and Capital Resources***

The following table and the discussion present the Company's cash activities on continuing basis for three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | 2025 |
| Net cash (used in) provided by: |  |  |
| Operating activities | $**(608876)** | $(984611) |
| Investing activities | **-** |  |
| Financing activities | **606022** | 513352 |
| Total net decrease in cash | $**(2854)** | $(471259) |

---

Our net cash used in operating activities of approximately $0.6 million for the three months ended March 31, 2026 resulted from a net loss of $0.8 million, offset by a non-cash adjustment of approximately $13,000 and a net cash change of $0.2 million from changes in operating assets and liabilities. Our net cash used in operating activities of approximately $1.0 million for the three months ended March 31, 2025 resulted from a net loss of $2.2 million, offset by a non-cash adjustment of $1.2 million and a net cash change of $40,000 from changes in operating assets and liabilities.

There was no cash used in investing activities for the three months ended March 31, 2026 and 2025.

The net cash provided by financing activities of $0.6 million for the three months ended March 31, 2026 is primarily due to $0.1 million net transfers from HCWC and $0.5 million cash proceeds from Sabby loan advance. The net cash provided by financing activities of $0.5 million for the three months ended March 31, 2025 is primarily due to $1.0 million net transfer from HCWC and $0.5 million cash payment of the credit line.

At March 31, 2026 and December 31, 2025, we did not have any material financial guarantees or other contractual commitments with vendors that are reasonably likely to have an adverse effect on liquidity.

Our cash balances are kept liquid to support our growing acquisition and infrastructure needs for operational expansion. Most of our cash and cash equivalent are concentrated in one financial institution and is generally in excess of the FDIC insurance limit. The Company has not experienced any losses on its cash. The following table presents the Company's cash position as of March 31, 2026 and December 31, 2025.

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | December 31, 2025 |
| Cash and cash equivalent | $**1137634** | $**1140488** |
| Total assets | $**1434534** | $**1467870** |
| Cash and cash equivalent as a percentage of total assets | **79.3%** | **77.7%** |

---

The Company reported a net loss from continuing operation of $0.8 million for the three months ended March 31, 2026. The Company also had negative working capital of $0.8 million. The Company expects to continue incurring losses for the foreseeable future.

The Company anticipates its current cash and its ability to draw up to $4.5 million under the Sabby Loan Agreement will be sufficient to meet projected operating expenses for the foreseeable future through at least twelve months from the issuance of the condensed consolidated financial statements.

**Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements.

**Critical Accounting Estimates**

Our management's discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments and contingencies at the date of the condensed consolidated financial statements.

We base our estimates on our historical experience, knowledge of our business and industry, current and expected economic conditions, the attributes of our products, the regulatory environment, and in certain cases, the results of outside appraisals. These estimates include useful lives and impairment of long-lived assets, deferred taxes and related valuation allowances, allocation of corporate general expenses, and the valuation of the assets and liabilities acquired in business combinations. We periodically re-evaluate our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.

**Seasonality**

We do not consider our business to be seasonal.

**Cautionary Note Regarding Forward-Looking Statements**

This report includes forward-looking statements including statements regarding retail expansion, the future demand for our products, the transition to vaporizer and other products, competition, the adequacy of our cash resources and our authorized Common Stock, and our continued ability to raise capital.

The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

The results anticipated by any or all of these forward-looking statements might not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include our future common stock price, customer acceptance of our products, and proposed federal and state regulation. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable to smaller reporting companies.

**ITEM 4. CONTROLS AND PROCEDURES**

We are required to report under Section 404(a) of Sarbanes-Oxley regarding the effectiveness of our internal control over financial reporting.

***Evaluation of Disclosure Controls and Procedures***

Our management, including our Principal Executive Officer and Principal Financial Officer, carried out an evaluation on internal controls as of March 31, 2026 in regard to the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report.

The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of the Company's management, including the Chief Executive Officer and Chief Financial Officer, the Company evaluated the effectiveness of the design and operation of its internal control over financial reporting based on the framework established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's internal control over financial reporting was ineffective as of March 31, 2026 and noted the material weaknesses as follows:

● Failure to have properly documented and designed disclosure controls and procedures and testing of the operating effectiveness of our internal control over financial reporting.

● Segregation of duties due to lack of personnel.

● The Company had ineffective design, implementation and, operation of controls over logical access, program change management, and vendor management controls. The Company's controls on IT should have included the following:

---

| | |
|:---|:---|
| ◌ | Appropriate restrictions that would adequately prevent users from gaining inappropriate access to the financially relevant systems. |
| ◌ | IT program and data changes affecting the Company's financial IT applications and underlying accounting records, should be identified, tested, authorized and implemented appropriately to validate that data produced by its relevant IT system(s) were complete and accurate. |
| ◌ | Obtaining and reviewing key third party service provider SOC reports. |

---

Our management concluded that considering internal control deficiencies that, in the aggregate, rise to the level of material weaknesses, we did not maintain effective internal control over financial reporting as of March 31, 2026 based on the criteria set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

***Planned Remediation***

Management continues to work to improve its controls related to our material weaknesses listed above. In order to achieve the timely implementation of the above, management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis:

● Continuing to increase headcount across the Company, with a particular focus on hiring individuals with strong internal control backgrounds and inventory expertise.

● Establishing policies and procedures in the IT area to mitigate data breach, unauthorized access and address segregation of duties, as well as review key third party service provider SOC reports.

We are currently working to improve and simplify our internal processes and implement enhanced controls, as discussed above, to address the material weaknesses in our internal control over financial reporting and to remedy the ineffectiveness of our disclosure controls and procedures. These material weaknesses will not be considered to be remediated until the applicable remediated controls are operating for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

***Changes in Internal Controls over Financing Reporting***

Except as detailed above, during the three months ended March 31, 2026, there were no significant changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

**PART II - OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS.**

There were two lawsuits in connection with alleged claimed battery defects for an electronic cigarette device. One had been dismissed by the court wherein the plaintiff settled with the Company's insurance carrier with no economic impact to the Company. In the second lawsuit, as of December 31, 2023, the Company had reached an arrangement with the plaintiff to resolve the matter, limiting potential exposure of the Company to $1.5 million which was reflected in accounts payable and accrued expenses, representing management's estimate of the probable settlement amount based on the current status of discussions. This arrangement was formalized by a signed agreement on July 1, 2024 and the Company accrued $1.5 million at June 30, 2024. As of May 31, 2025, the Company already paid $1,500,000 in full.

On September 26, 2023, HCMC filed a patent infringement lawsuit against R.J. Reynolds Vapor Company ("RJR") in the U.S. District Court for the Middle District of North Carolina in connection with HCMC's assertions that RJR's Vuse electronic cigarette infringes one of HCMC's patents.

On November 17, 2023, RJR filed a motion to dismiss the action. HCMC opposed on December 22, 2023.

On September 18, 2024, RJR filed an inter partes review of the patent-in-suit at the United States Patent and Trademark Office ("USPTO").

In March 2026, the Patent Trial and Appeal Board issued a decision in favor of RJR in the ongoing patent dispute. The Company is currently evaluating its options and expects to file an appeal of the ruling.

From time to time the Company is involved in legal proceedings arising in the ordinary course of our business. We believe that there is no other litigation pending that is likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations as of March 31, 2026. With respect to legal costs, we record such costs as incurred.

**ITEM 1A. RISK FACTORS.**

Not Applicable.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.**

Not Applicable.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES.**

None.

**ITEM 4. MINE SAFETY DISCLOSURES.**

Not Applicable.

**ITEM 5. OTHER INFORMATION.**

Not Applicable.

**ITEM 6. EXHIBITS.**

See the exhibits listed in the accompanying "Index to Exhibits."

**INDEX TO EXHIBITS**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| **Exhibit**<br>**No.** | <br>**Exhibit Description** | **Form** | **Date** | **Number** | **Filed or Furnished**<br>**Herewith** |
| 10.1 | [Loan Agreement, dated as of March 27, 2026, among Healthier Choices Management Corp., and Sabby Volatility Warrant Master Fund, Ltd.](https://www.sec.gov/Archives/edgar/data/844856/000149315226015019/ex10-1.htm) | 8-K | 4/3/2026 | 10.1 |  |
| 10.2 | [Letter Agreement, dated March 27, 2026, by and between HCMC and Hal Mintz](https://www.sec.gov/Archives/edgar/data/844856/000149315226015032/ex10-1.htm) | 8-K | 4/3/2026 | 10.1 |  |
| 31.1 | [Certification of Principal Executive Officer (302)](ex31-1.htm) |  |  |  | Filed |
| 31.2 | [Certification of Principal Financial Officer (302)](ex31-2.htm) |  |  |  | Filed |
| 32.1 | [Certification of Principal Executive Officer (906)](ex32-1.htm) |  |  |  | Furnished \* |
| 32.2 | [Certification of Principal Financial Officer (906)](ex32-2.htm) |  |  |  | Furnished \* |
| 101.INS | Inline XBRL Instance Document |  |  |  | Filed |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  | Filed |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  | Filed |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  | Filed |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  | Filed |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  | Filed |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |  |  |  | Filed |

---

\* This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | HEALTHIER CHOICES MANAGEMENT CORP. | HEALTHIER CHOICES MANAGEMENT CORP. |
| Date: May 14, 2026 | By: | */s/ Jeffrey Holman* |
|  |  | Jeffrey Holman |
|  |  | Chief Executive Officer |
| Date: May 14, 2026 | By: | */s/ John Ollet* |
|  |  | John Ollet |
|  |  | Chief Financial Officer |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

I, Jeffrey Holman, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly
 report on Form 10-Q of Healthier Choices Management Corp.;

2. Based on my knowledge,
 this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
 made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
 report;

3. Based on my knowledge,
 the financial statements, and other financial information included in this report, fairly present in all material respects the financial
 condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's
 other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
 in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
 and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure
 controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
 information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
 particularly during the period in which this report is being prepared;

b) Designed such internal
 control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
 external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness
 of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness
 of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report
 any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent
 fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
 reasonably likely to materially affect, the registrant's internal control over financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's
 other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
 to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the
 equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies
 and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
 affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not
 material, that involves management or other employees who have a significant role in the registrant's internal control over
 financial reporting.

Date: May 14, 2026

---

| |
|:---|
| */s/ Jeffrey Holman* |
| Jeffrey Holman |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

I, John Ollet, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this quarterly
 report on Form 10-Q of Healthier Choices Management Corp.;

2. Based on my knowledge,
 this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
 made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
 report;

3. Based on my knowledge,
 the financial statements, and other financial information included in this report, fairly present in all material respects the financial
 condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's
 other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
 in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
 and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure
 controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
 information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
 particularly during the period in which this report is being prepared;

b) Designed such internal
 control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
 external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness
 of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness
 of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report
 any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent
 fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is
 reasonably likely to materially affect, the registrant's internal control over financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's
 other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
 to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the
 equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies
 and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
 affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not
 material, that involves management or other employees who have a significant role in the registrant's internal control over
 financial reporting.

Date: May 14, 2026

---

| |
|:---|
| */s/ John Ollet* |
| John Ollet |
| Chief Financial Officer |
| (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Healthier Choices Management Corp. (the "Company") on Form 10-Q for the period ending March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof, I, Jeffrey Holman, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The quarterly report fully
 complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained
 in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2026

---

| |
|:---|
| */s/ Jeffrey Holman* |
| Jeffrey Holman |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Healthier Choices Management Corp. (the "Company") on Form 10-Q for the period ending March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof, I, John Ollet, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The quarterly report fully
 complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

2. The information contained
 in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2026

---

| |
|:---|
| */s/ John Ollet* |
| John Ollet |
| Chief Financial Officer |
| (Principal Financial Officer) |

---